Clinical Trial

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 30, 2024 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a full-length AAV vector-based gene therapy targeting RPGR protein.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-16; most recent amendment 2024-10-28.
Trial Details
NCT Number NCT06275620
Lead Sponsor Beacon Therapeutics
Conditions X-Linked Retinitis Pigmentosa
Enrollment 24 participants
Start Date 2023-11-14
Primary Completion 2025-11 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2024-10-30